Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02882191 · ClinicalTrials.gov registry record · Phase 2
Evaluation of the Efficacy and Safety of LevoCept
A Phase 2 study, sponsored by Sebela Women's Health.
- Completed
- Registry status
- Phase 2
- Development phase
- 279
- Enrollment target
NCT02882191: Completed Phase 2 study, sponsored by Sebela Women's Health.
NCT02882191 is a Phase 2 study that has completed, run by Sebela Women's Health. The registered enrollment target is 279 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (110% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02882191, a Phase 2 study, has completed, sponsored by Sebela Women's Health.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 279 participants
- Enrollment target
Study Summary
To evaluate the effectiveness, device placement, safety, and tolerability of LevoCept to support commencing a Phase III Clinical Study
Primary Outcome
Contraceptive efficacy through 3 years of use, as assessed by the Pearl Index. The Pearl Index is calculated as the number of on-treatment pregnancies per 100 woman-years of exposure. On-treatment pregnancy is defined as the estimated conception date being on or after the insertion date (must be a successful insertion) and no more than 7 days after the study drug is removed or expelled. One women year is defined as comprising thirteen 28-day cycles. A lower Pearl Index indicates greater contrace
Interventions
- DRUG LevoCept
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 279 participants |
| Start Date | 2016-11 |
| Est. Completion | 2020-11-12 |
| Phase | Phase 2 |
What the finished NCT02882191 record still lists
NCT02882191 is an interventional study that assigns participants to a tested intervention. The registered 279 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (110% higher).
The record links to 0 conditions, and to 1 intervention - of which LevoCept is the first listed.
NCT02882191 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02882191 about?
NCT02882191 is a clinical study titled "Evaluation of the Efficacy and Safety of LevoCept". To evaluate the effectiveness, device placement, safety, and tolerability of LevoCept to support commencing a Phase III Clinical Study
What is the current status of trial NCT02882191?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 279 participants. The study started on 2016-11. Estimated completion is 2020-11-12.
What interventions are being tested in trial NCT02882191?
The interventions under investigation include: LevoCept (DRUG).
Who is sponsoring clinical trial NCT02882191?
This trial is sponsored by Sebela Women's Health, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02882191's enrollment target sits among peer trials
279 201st of 2000 higher than 1,799 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04783857 · 279 participants · Phase 4
Modifying Progesterone and Estradiol Levels to Prevent Postpartum Cigarette Smoking Relapse and Reduce Secondhand Smoke Exposure in Infants and Children
- NCT05407324 · 279 participants · Phase 2
Dazucorilant in Patients With Amyotrophic Lateral Sclerosis
- NCT06299748 · 279 participants
A Worldwide Pregnancy Safety Study to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to Efgartigimod During Pregnancy and/or Breastfeeding.
- NCT06582784 · 279 participants · NA
IMPACT (IMproving Proactive Approaches for Cancer Survivors' Mental Health Treatment)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia